

Abstract Sessions

Titles and presenting authors

Session 1 (Wednesday): Preanalytics, sample transport & stability

1.1 Influence of pneumatic tube system transport on cell count and spectrophotometry in cerebrospinal fluid, *Presented by Marcus Clarin*

1.2 Sample contamination by external bioidentical 17 β -estradiol – an emerging concern in clinical laboratories, *Presented by Marie Larsson*

1.3 Pre-analytical pitfalls: missing and mislabeled samples for the limited sampling strategy for mycophenolate testing, *Presented by Elke Hoffman-Lücke*

1.4 Effect of pneumatic tube transport on venous blood gas and biochemical parameters in lithium heparin tubes, *Presented by Linda Ø. Henriksen*

1.5 Analyte Stability Using a Pre-Analytical Protocol for Handling Blood Samples from Patients with Cold Autoimmune Hemolytic Anemia, *Presented by Jesper S. Johansen¹*

1.6 Stability study of key chemistry analytes in pleural and peritoneal fluid: defining storage times under refrigerated conditions to ensure result quality, *Presented by Pernille O. Andersen*

1.7 Leaching Profile of Primary Packaging and Its Influence on Analyte Recovery in Quality Control Materials, *Presented by Khalisah L. Zulkefli*

1.8 Preanalytical Errors in Arterial and Venous Blood Gas Analyses – Are There Differences Depending on Clinical Setting?, *Presented by Gitte Olander*

Session 2 (Wednesday): Analytical performance, interference & comparability

2.1 Analytical performance comparison of three methods for serum 25-hydroxyvitamin D measurement,
Presented by Giuseppe Banfi

2.2 In Vitro Interference of Acetylsalicylic Acid on HbA1c Measurement by HPLC Leading to Falsely Elevated Results, *Presented by Daniel Kriz*

2.3 Comparability of Serum indices measured on Roche Cobas c501 and Cobas c503 analyzers, *Presented by Natalja Gumenjuk*

2.4 Detection and interference of Hemoglobin variants with HbA1c analysis using the two analysis modes on the novel Tosoh GR01 analyzer, *Presented by Helle Pilgaard Kristiansen*

2.5 Performance evaluation of an avian antibody-based particle-enhanced turbidimetric assay for free kappa and lambda light chains, *Presented by Anders Larsson*

2.6 Study design is crucial when investigating non-hemoglobin hemolysis interference, *Presented by Mette Oestergaard*

2.7 Is external quality control relevant for performance evaluation of Extended Inflammatory Parameters on Sysmex automated haematology analyser?, *Presented by Gitte Tindbæk*

2.8 Evaluation of the EXIAS e|1 Electrolyte Analyzer for Measurement of Ionized Calcium in Serum,
Presented by Julie Grønvik & Sanne Kurek

Session (Wednesday) 3: Reference intervals, decision limits & interpretation

3.1 Approach to the Verification of Neonatal Reference Values for Red Blood Cell Parameters, Presented by Dmitri Šišmintsev

3.2 Use of HbA1c in Patients with Thalassemia or Hemoglobin Variants: Recommendations from a Norwegian Working Group, Presented by Eva C. Langsjøen and Gunhild Ø. Fosse.

3.3 Evaluation of Active B12 on Atellica IM Analyser to predict B12 deficiency, Presented by Christina Jungar

3.4 Proposed age-, gender- and platform-specific ferritin reference intervals in Sweden using indirect and dynamic approaches, Presented by Gustav Hallén

3.5 Plasma pTau217 – Preanalytical Stability and Reference Interval, Presented by Silje H. Christensen

3.6 Indirect Reference Interval Estimation for Serum Ferritin Across Multiple Analytical Platforms: Assay-Specific Reference Intervals or Harmonization?, Presented by Jacob Rudjord Therkildsen

3.7 Establishment of diagnostic cutoffs for plasma p-tau217 immunoassays, Presented by Joel Simrén

3.8 eGFR-stratified reference intervals for Siemens N Latex serum free light chains in a large routine laboratory population, Presented by Johan Bjerner

Session 4 (Wednesday): EQA, quality systems & laboratory management

4.1 An EQA-scheme connecting the preanalytical, analytical and postanalytical phases, *Presented by Anna Borup*

4.2 EQA of the pre- and post-analytical phases, *Presented by Anna Borup*

4.3 Beyond Stability: A Risk-Based Approach to Selection of Analyte Sources for Patient-Like Control Materials Under IVDR, *Presented by Lisa Tietze*

4.4 A new EQA scheme for Immunosuppressants: applicability for mass spectrometry and other analytical methods, *Presented by Kristel Virtanen*

4.5 How do clinical laboratories define and monitor turnaround times? Findings from an EQA questionnaire, *Presented by Kristel Virtanen*

4.6 Visualization of traceability information in longitudinal external quality assessment reports, *Presented by Magnus Hansson*

4.7 EQAlity for a better world! How do we prepare proficiency test reports for next generation laboratory information system, *Presented by Jens B. Larsen*

4.8 Using AI to build a free web calculator for laboratory analytical quality assessment, *Presented by Sutirtha Chakraborty*

Session 5 (Wednesday): Immunology, inflammation & infection

5.1 Outcome prediction and sepsis monitoring by plasma HNL, *Presented by Per Venge*

5.2 Circulating biomarkers for risk stratification in chronic obstructive pulmonary disease: a systematic review, *Presented by Nikolaos Trakas*

5.3 Vitamin D – mediated Modulation of Macrophage Phenotype and Fibrotic Signaling, *Presented by Freja H. Pedersen*

5.4 ADA in Plain Sight: S/N Ratios Unmask Low-Titre Anti-Drug Antibodies, *Presented by Lise Pedersen*

5.5 Reliable type-1 diabetes autoantibody profiling from dried blood spots using autoantibody detection by agglutination-PCR (ADAP) suggests potential for home-based testing, *Presented by Verena H Jensen*

5.6 Human monocyte-derived macrophages differentiated with M-CSF, GM-CSF, or both display similar phagocytosis and broadly overlapping phenotypes, *Presented by Henriette N. Friis*

5.7 Circulating microRNA signatures as potential biomarkers for differentiating tuberculosis disease from tuberculosis infection, *Presented by Søren Feddersen*

Session 6 (Wednesday): Neurology, cardiovascular & precision diagnostics

6.1 Blood-borne biomarkers in the diagnosis of Diabetic Peripheral Neuropathy, *Presented by Charlotte W. Juul*

6.2 Evaluation of NfL biomarker in patients with Relapsing Multiple Sclerosis in Greece, *Presented by Loukia Psaridi*

6.3 CYP2C19 loss-of-function alleles are not associated with recurrent cardiovascular events in a Danish clopidogrel cohort, *Presented by Michael A Andersen*

6.4 The effect of an intervention on appropriate use of Brain Natriuretic Peptide testing in general practice: a one-year follow-up, *Presented by Louise Lylloff*

6.5 A Danish National Pipeline for Pharmacogenomic Analysis, Interpretation and Reporting, *Presented by Peter Breining*

6.6 Beyond Age: AHRR Methylation for Abdominal Aortic Aneurysm Screening, Progression, and Peripheral Arterial Disease, *Presented by Lasse M Obel*

6.7 Computational Analysis of Whole-Slide Histological Images of Acute Ischemic Stroke Thrombi, *Presented by Romina Medeiros*

6.8 Closing the Diagnostic Gap: Reclassification of an HPS4 VUS Using RNA Sequencing, *Presented by Peter H. Nissen*

Session 7 (Thursday): Endocrinology, metabolism & screening

7.1 Metformin and vitamin B12 deficiency: A prevalence study, *Presented by Kristina Laugesen*

7.2 Comparison of Diabetes-Related Metabolic Biomarkers in Dried Blood Spots (DBS) and Venous Plasma Using the Meso QuickPlex SQ120 Platform, *Presented by Frederikke Høgh*

7.3 Automated immunoassay testosterone analysis for screening men in primary care: Saving time and costs without compromising quality, *Presented by Ninna H. Tougaard*

7.4 Cohort Profile: The Danish Vitamin D Cohort (DanVitD), Integrating Nationwide Clinical Vitamin D Measurements with Danish Health Registries, 2000–2025, *Presented by Anne Juhl Nielsen*

7.5 Evaluation of commercially available immunoassays for urinary luteinizing hormone measurement in assessing pubertal onset, *Presented by Joel Björklund*

7.6 Glucagon Increases ACTH, Cortisol and GH Secretion Independently of Increments in Blood Glucose, and GCGR is Expressed in the Human Nucleus Tractus Solitarius, *Presented by Elvar Már Sturlaugsson Jóhannuson*

7.7 High plasma 18 β -glycyrrhetic acid levels are associated with more intensive antihypertensive treatment, resistant hypertension and apparent mineralocorticoid excess in patients with type 2 diabetes, *Presented by Jakob L Wetzche*

Session 8 (Thursday): Mass spectrometry, automation & analytical innovation

8.1 Validation of the EXENT® System, an automated MALDI-TOF mass spectrometry system for detection and quantification of MProtein, *Presented by Marcus Clarin*

8.2 ICP-MS validation of total and exchangeable copper measurements for routine clinical use in Wilson's disease diagnosis and monitoring, *Presented by Berit P. Jensen*

8.3 24/7 fully automated therapeutic drug analysis for research projects by LC-MS/MS, *Presented by Magnus Olin*

8.4 High Throughput Quantification of Immunosuppressant Drugs in Human Blood by multichannel LCMS using Shimadzu NexeraMX and LCMS8050RX, *Presented by Magnus Olin*

8.5 Multiplexed absolute quantification of plasma complement proteins using mass spectrometry, *Presented by Magnus Hansson*

8.6 Beyond Immunoassays: Measurement of Thyroid Hormones by Mass Spectrometry, *Presented by Anher Saeed*

8.7 First Danish Experience with Automated Blood Collection Using the Aletta Autonomous Robotic Phlebotomy Device: Patient Acceptance, Feasibility, and Sample Quality, *Presented by Charlotte Gils*

Session 9 (Thursday): POCT, clinical implementation & diagnostic innovation

9.1 Reduction in unnecessary ECG recordings, *Presented by Charlotte Gils*

9.2 An ultrasensitive signal amplified immunoassay for quantitation of DOPA decarboxylase (DDC) in cerebrospinal fluid, *Presented by Holger J. Møller*

9.3 The Biochemical Research Support Unit (BFS) supports high-quality international research at Aarhus University Hospital, *Presented by Mette M. Nielsen*

9.4 Point-of-care diagnosis of acute infections, *Presented by Per Venge*

9.5 Evaluation of a novel point-of-care testing device for NT-proBNP assessment in prehospital settings, *Presented by Anders Larsson*

9.6 Vitamin D Testing in Norwegian Primary Care: A Comparative Audit of Two Health Regions in Norway, *Presented by Sutirtha Chakraborty*

9.7 Prehospital Blood Sampling as a Tool to Improve Patient Flow in the Emergency Department, *Presented by Mads Nybo*

9.8 Development of anti-Troponin I IgG and anti-Troponin T IgG immunoassay, *Presented by Martin T. Pedersen*

Session 10 (Thursday): Hematology, coagulation & red-cell disorders

10.1 Biochemical and Genetic characterization of Porphyria Cutanea Tarda (PCT) in Sweden, *Presented by Yasmin Elgendy*

10.2 Pseudothrombocytosis in a Patient with Cryoglobulinemia Across Three Different Automated Haematology Platforms, *Presented by Rie McGrail*

10.3 A structural model of the complex TfR2 with wild type and C282Y mutant HFE based on available experimental data, *Presented by Sonia Distante*

10.4 Recognition and Early Diagnosis of Bleeding Disorders in Women: the RED-WOMEN study, *Presented by Kathrine B. Faldborg*

10.5 Maternal determinants of platelet levels during pregnancy in women with and without myeloproliferative neoplasms: a Danish register-based cohort study, *Presented by Christina C. S. Schnohr*

10.6 Reference Intervals for ROTEM-tPA: Whole-Blood Fibrinolysis Assessment in Healthy Adults, *Presented by Anne L Malte*

10.7 Fibrinogen Aarhus, FGA c.112A>G (p.Arg38Gly): A recurrent Danish Variant Associated with Dysfibrinogenemia Suggesting a Possible Founder Effect, *Presented by M. Vakur Bor*

10.8 Cold agglutinin warnings are associated with decreased blood haemoglobin concentration, *Presented by Kasper Birch Kristensen*

Session 11 (Thursday): Cancer biomarkers & experimental oncology

11.1 The Effect of Moringa leaf extract on Cisplatin-Induced Apoptosis in gastric cancer cells, *Presented by Dr. Shadia Al Bahlani*

11.2 Serum soluble SIRP α as a potential prognostic biomarker after surgery for esophageal cancer, *Presented by Kristian W. Antonsen*

11.3 Blood biomarkers investigated in the NIMBLE study, *Presented by Søren Egstrand, Dept. of Clinical Biochemistry, Rigshospitalet, Copenhagen, Denmark*

Dept. of Clinical Biochemistry, Herlev and Gentofte Hospital, Herlev, Denmark

11.4 A redox-disruptive photodynamic therapy approach driven by Hypericum Perforatum L. extract to overcome cellular defense mechanisms in glioblastoma, *Presented by Selin F. Güney*

11.5 Photo-Chemo Synergy: Enhancing Etoposide Efficacy with Photosensitizers in Glioblastoma Multiforme, *Presented by Mehmed M. Yiğiter*

11.6 Low levels of soluble signal-regulatory protein alpha (sSIRP α) identifies patients with a favourable prognosis in lymphoid malignancies, *Presented by Julie S. Østergaard*

Session 12: Gastroenterology (Thursday), hepatology, bone & nutrition

12.1 Influence of bowel preparation on routine blood biomarkers prior to colonoscopy, *Presented by Line H. Fly*

12.2 Serum concentrations of gastric intrinsic factor – A pilot study on patients undergoing bariatric surgery, presenting with portal hypertension, or suspected of pernicious anemia, *Presented by Eva Greibe*

12.3 Keratin 7 protein presence in stool is indicative of active pediatric-onset IBD, *Presented by Maria A. Ilomäki*

12.4 Development of an ELISA-based assay for fecal keratin 7 detection in inflammatory bowel disease, *Presented by Ekta Kotharkar*

12.5 Patients with autoimmune, cholestatic and metabolic liver diseases share a common conjugated bile acid phenotype, *Presented by Jesper S. Kelleman*

12.6 Withdrawal of Alendronate Treatment of Osteoporosis in Rheumatoid Arthritis: Biomarker results from the randomised controlled ALOSTRA trial, *Presented by Anne-Birgitte Garm Blavnsfeldt*